Skip to main content
. 2015 May 13;4(7):e1014232. doi: 10.1080/2162402X.2015.1014232

Figure 3.

Figure 3.

Depletion of CD4+ T cells in IL-10−/− mice facilitates tumor rejection. Four doses of anti-CD8 (53-6.72), anti-CD4 (GK1.5), or control antibodies (2A3 or LTF-2) were injected intraperitoneally into WT (A, C) and IL-10−/− mice (B, D) at a dose of 400 μg/per mouse at 4-day intervals beginning on day 1 after J558 tumor cell injection. Four to 5 mice were used per group. Data shown are representative of 2 to 3 experiments with similar results. **P < 0.01 by Student t test.